GSK new generation IL-5 inhibitor, depemokimab shows promising results in patients with CRSwNP | iPharmaCenter
GSK has announced encouraging results from its phase III clinical trials, ANCHOR-1 and ANCHOR-2, for depemokimab in treating chronic...
top of page
Hidradenitis Suppurativa | News | Updates | 2024 | iPharmaCenter
January 08, 2024 AbbVie aims to bring another HS therapy after Humira, announced positive Phase 2 trial of lutikizumab Positive outcomes...
Hidradenitis suppurativa news | Blogs | iPharmaCenter
AbbVie aims to advance its immunology pipeline by initiating a global Phase 3 trial of Rinvoq (upadacitinib) for Hidradenitis Suppurativa...
Atopic dermatitis news
Eli Lilly announced the positive results of Phase 3 clinical trial of its drug, lebrikizumab, in treating atopic dermatitis. There was a...
Systemic Lupus Erythematosus | News | Blogs | iPharmaCenter
AbbVie announced it would move Rinvoq (upadacitinib) into Phase 3 clinical trials to treat systemic lupus erythematosus (SLE). Rinvoq is...
Immunology | Rheumatology | Autoimmune disorders | News | Safety of JAK inhibitors | iPharmaCenter
EMA takes measures to reduce the risk of severe side effects with JAK inhibitors. The Committee for Medicinal Products for Human Use...
IBD News | Ulcerative colitis and Crohn's Disease |
AbbVie published Phase 3 clinical trials of Skyrizi in Crohn's Disease. AbbVie announced that The Lancet had published the induction and...
Psoriatic Arthritis News | FDA Approvals | EMA Approvals | PMDA Approvals | NMPA China Approvals
AbbVie's immunology portfolio in Europe is strengthened with Skyrizi approval for psoriatic arthritis Approval is based on the trial...
bottom of page